Trial Profile
A Phase 1, Open Label, Study in Healthy Female Subjects to Describe GSK1349572 Exposure in Blood, Cervicovaginal Fluid, and Cervical and Vaginal Tissue Following Single and Multiple Dosing of GSK1349572.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- 08 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 08 Nov 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 01 Aug 2011 New trial record